Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity.
about
Overnutrition Determines LPS Regulation of Mycotoxin Induced Neurotoxicity in Neurodegenerative DiseasesExploring the accessible conformations of N-terminal acetylated α-synucleinGenetically engineered mouse models of Parkinson's diseaseAge-dependent effects of A53T alpha-synuclein on behavior and dopaminergic functionDJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activityA novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formationCovalent α-synuclein dimers: chemico-physical and aggregation properties.Effects of curvature and composition on α-synuclein binding to lipid vesiclesTauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domainEfficient, Traceless Semi-Synthesis of α-Synuclein Labeled with a Fluorophore/Thioamide FRET PairDrug discovery in Parkinson's disease-Update and developments in the use of cellular models.Identification of novel SHPS-1-associated proteins and their roles in regulation of insulin-like growth factor-dependent responses in vascular smooth muscle cells.A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activityPotential role of alpha-synuclein and metallothionein in lead-induced inclusion body formation.Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease.Structural and mechanistic basis behind the inhibitory interaction of PcTS on alpha-synuclein amyloid fibril formation.α-Synuclein and neuronal cell death.Advances in electrochemical detection for study of neurodegenerative disorders.Disulfide bonds in amyloidogenesis diseases related proteins.The prion hypothesis of Parkinson's disease.Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson's Disease.Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease.Identification and functional characterization of an aggregation domain in long myosin light chain kinase.Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization.Metal chelator EGCG attenuates Fe(III)-induced conformational transition of α-synuclein and protects AS-PC12 cells against Fe(III)-induced death.Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.Cysteine misincorporation in bacterially expressed human alpha-synuclein.Mutant protein kinase Cgamma found in spinocerebellar ataxia type 14 is susceptible to aggregation and causes cell death.Hsp90 Co-chaperone p23 contributes to dopaminergic mitochondrial stress via stabilization of PHD2: Implications for Parkinson's disease.
P2860
Q26774272-41842DD4-F7B4-419B-92BC-17A3EB75B14EQ26852660-15C4FE3B-9947-49EE-8AEF-001511559829Q26852964-F9DC7601-BBD9-430E-8FB2-9F26DFD6547BQ27330366-EC79079F-AD7B-4AE2-8E31-25DED5FA87E9Q33326619-4165340E-2E64-428E-A672-31A3F48F6E53Q33576321-BAC8C44C-0026-4D70-ABCD-898DAD11C7A3Q34010946-924825CB-1D95-4645-8DA2-A0CCFA8050DCQ34524912-55AE556D-C5A8-44D9-9AD2-2617A5FF66ECQ34590790-8BC99DFA-C187-4131-8046-8967BE2C10C2Q34704153-F856834F-CCAB-4AB0-91B4-E792A3C48C76Q34917354-6C98EDF4-CE0C-4B58-8431-85A9EC921099Q36527246-0BE7C36A-56A6-44D0-B44A-299F7E34580CQ36584899-804FA815-8313-4DA2-944F-7A31F1068A8DQ36680414-2B43CF9F-898A-496E-A7DF-6984BED24A23Q37258075-1E0A9049-0252-4375-B069-1C242C27AA42Q37290672-F301908C-1E4D-4631-ABDF-FD48DC5606E5Q37303879-8F3AAAA7-4AA5-418D-8B1A-B3A1CD39D624Q37357416-421FB54C-EC6B-43F2-B3E3-89560C4DBECBQ37482190-51C67D82-21AC-42F6-A0C7-007C6332C1D7Q38039369-B28076CA-6CE7-4FE3-B36E-8E6EE75A0F4AQ38093077-B673D296-39F0-4DA6-BFD3-0A20D8B906E4Q38113990-BF1DFC46-B5FF-4506-B963-5929BCF7A1B7Q38418624-F36D2967-10F7-43E0-BF00-C07348DD01CCQ38722255-98A808B1-2873-4A4C-B489-9CDE7DA0562EQ39582058-B7DFAD38-C47D-42CC-B0B5-850466DF25F0Q39993652-704560C3-5CEF-4A35-AE4C-A714AF02EAB0Q42246480-4CDD5DD0-865C-4C57-9083-5FA39B56E140Q46323541-52800244-98A5-4B0E-BDF1-7633CB3284B2Q46780013-517AAFF6-F456-4D35-B388-2297A1B23F00Q46972456-F7236814-0E9B-4B27-9311-9AC29E6AD9F2Q50764411-33CCBBDD-2D45-4C88-8A28-E32E7900067DQ51767924-9A5D0EBF-7BA7-4FF0-8319-4479EAF67584
P2860
Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Tyrosine-to-cysteine modificat ...... egation and cellular toxicity.
@en
type
label
Tyrosine-to-cysteine modificat ...... egation and cellular toxicity.
@en
prefLabel
Tyrosine-to-cysteine modificat ...... egation and cellular toxicity.
@en
P2860
P356
P1476
Tyrosine-to-cysteine modificat ...... egation and cellular toxicity.
@en
P2093
Curt R Freed
Wenbo Zhou
P2860
P304
10128-10135
P356
10.1074/JBC.M307563200
P407
P577
2003-12-29T00:00:00Z